Material properties and osteoporosis

Paschalis, Eleftherios P.; Klaushofer, Klaus; Hartmann, Markus

doi:10.12688/f1000research.18239.1

Cited by 8 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the inLux SEM Raman interface is particularly advantageous in (i) reducing variabilities in ROIs as both investigations are performed at the same location, (ii) increasing processing time, as there is no longer the need to remove the specimen from the SEM chamber to bring it to the Raman microscope, and (iii) avoiding contamination and sample damaging while transferring between systems. Indeed, in-SEM Raman spectroscopy has been reported as a superior technique than separated SEM and Raman imaging for correlative microscopy This is of interest as there is increasing demand for the determination of bone material properties and alterations in bone specimens from patients suffering of idiopathic osteoporosis and bone fragility 28 . A limitation of this study is that the native tissue specimens were dehydrated and embedded in polymethylmethacrylate.…”

Section: Discussionmentioning

confidence: 99%

Raman mineral-to-matrix ratios correlate with weight percentage mineral-to-matrix ratio determined by in-SEM Raman imaging of bone tissue

Mabilleau,

Boorman,

Diniz

2024

Preprint

View full text Add to dashboard Cite

Raman imaging combined with scanning electron microscopy (SEM) is a powerful technique that allows for topographical, chemical and structural correlative multi-scale imaging. It provides the perfect tool to determine which of the Raman mineral-to-matrix ratios represent the best parameter to accurately measure the degree of mineralization of the bone matrix using quantitative backscattered electron imaging (qBEI) as the reference methodology. Indeed, previous studies evidenced that the v2PO4and v4PO4vibrational modes were less sensitive to laser polarization than the v1PO4. However, using the v2PO4or v4PO4requires a longer acquisition time or lower spectral resolution. In the present study, we evaluated the correlation between mineral-to-matrix ratios computed from v1PO4and v2PO4in a human bone sample retrieved from orthopaedic surgery during hip replacement and wt% mineral / wt% organic matrix obtained from qBEI using the inLux SEM Raman interface. We reported here that all mineral-to-matrix ratios were significantly linearly correlated with wt% mineral / wt% organic matrix and that v1PO4/CH2exhibited the strongest correlation coefficient (r=0.880). This study suggests that the v1PO4is still a valid Raman peak to estimate the mineral-to-matrix ratio in bone samples and can be used to diagnose bone fragility disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Raman mineral-to-matrix ratios correlate with weight percentage mineral-to-matrix ratio determined by in-SEM Raman imaging of bone tissue

Mabilleau,

Boorman,

Diniz

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Microscopic evaluation of bone tissue reveals basic morpho-structural units predominantly found in cortical bone, known as osteons (21,22). Most of the bone volume is occupied by the bone matrix, inhabited by cells with specific functions: bone-forming cells called osteoblasts, bone-resorbing cells called osteoclasts, and the most numerous cells that act as bone remodeling orchestrators known as osteocytes (18,23). Going further to the submicroscopic level, it is evident that osteons consist of several concentric rings known as lamellae, while one lamella is made of many collagen fibers (Figure 1).…”

Section: Structur Al Morphology Of Bone Tissue: Short Overviewmentioning

confidence: 99%

Structural basis of increased bone fragility in aged individuals: Multi-scale perspective

Jadžić,

Đurić

2024

Medicinska istraživanja

View full text Add to dashboard Cite

Numerous epidemiological studies have shown that increased bone fragility and a higher risk of fractures are present in the aged, which reduces their quality of life and represents a significant socio-economic burden for the healthcare system. However, morphological and structural determinants underlying increased bone fragility have yet to be fully explained. This paper aimed to provide an overview of modern studies that dealt with determinants of increased bone fragility, analyzing different hierarchical levels of bone tissue organization (macro-, micro-, and nano-levels) in aged individuals and individuals with chronic comorbidities (mainly in individuals with chronic liver disease, renal disorders, and type 2 diabetes mellitus). Also, variable frequency of fractures at different skeletal sites in aged persons and individuals with chronic diseases was shown, indicating that aging-related bone loss is not a uniform process. A complete understanding of the spatial pattern of impaired bone quality can aid in the targeted evaluation of individualized fracture risk. Establishing a firm connection between the results of the clinical assessment of bone status and the analysis of numerous structural and mechanical bone properties (on various hierarchical levels) can represent a solid base for developing adequate guidelines and algorithms for prevention and treatment of increased bone fragility in aged individuals and individuals with chronic diseases.

show abstract

“…At the same time, due to the destruction of bone tissue structure, it becomes difficult to bear bone implants in the human body, leading to the failure rate of fracture fixation up to 10% to 25%. [ 3 4 ] With the extension of the human life span and the development of social aging, fractures caused by osteoporosis not only greatly increase the morbidity and mortality of the elderly, but also significantly increase the economic burden of public social health. [5] OP can occur at any age, but it is more common in postmenopausal women and older men.…”

Section: Introductionmentioning

confidence: 99%

Minodronate in the treatment of osteoporosis

Liu¹,

Chen²,

Ye³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: The goal of this study was to review relevant randomized controlled trials or case-control studies to determine the clinical efficacy of minodronate in the treatment of osteoporosis. Method: The relevant studies were identified on PubMed, Cochrane, and Embase databases using appropriate keywords. Pertinent sources in the literature were also reviewed, and all articles published through October 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference, and 95% confidence interval (95% CI) to evaluate and synthesize outcomes. Result: Thirteen studies comprising 3740 patients were included in this study. Compared with other drugs, minodronate significantly decreased N-telopeptide of type I collagen/creatinine (weighted mean difference [WMD]: –13.669, 95% confidence interval [CI]: –23.108 to –4.229), bone alkaline phosphatase (BAP) (WMD: –1.26, 95% CI: –2.04 to –0.47) and tartrate-resistant acid phosphatase 5b (WMD: –154.11, 95% CI: –277.85 to –30.37). Minodronate combined with other drugs would significantly decrease BAP (WMD: –3.10, 95% CI: –5.20 to –1.00) than minodronate. Minodronate-naïve would significantly decrease BAP (WMD: –3.00, 95% CI: –5.47 to 0.53) and tartrate-resistant acid phosphatase 5b (WMD: –128.20, 95% CI: –198.11 to –58.29) than minodronate-switch. The incidence of vertebral fracture was significantly decreased in the minodronate group than the other drugs (relative risk: 0.520, 95% CI: 0.363–0.744). Conclusion: Minodronate has better clinical efficacy in the treatment of osteoporosis than other drugs (alendronate, risedronate, raloxifene, or eldecalcitol).

show abstract

Material properties and osteoporosis

Cited by 8 publications

References 81 publications

Raman mineral-to-matrix ratios correlate with weight percentage mineral-to-matrix ratio determined by in-SEM Raman imaging of bone tissue

Raman mineral-to-matrix ratios correlate with weight percentage mineral-to-matrix ratio determined by in-SEM Raman imaging of bone tissue

Structural basis of increased bone fragility in aged individuals: Multi-scale perspective

Minodronate in the treatment of osteoporosis

Contact Info

Product

Resources

About